CYP2B6 and ABCB1 genotypes predict methadone plasma exposure among patients on maintenance therapy against opioid addictions in Tanzania.

Sabina MugusiRajabu Hussein MnkugweAnna A SangaAzreen SalahuddinVictoria BarclayGrace ShayoMarja-Liisa DahlEleni Aklillu

Published in: British journal of clinical pharmacology (2024)

Approximately one in six opioid-addicted Tanzanian patients are methadone slow metabolizers, influenced by genetic factors. Both the CYP2B6 and ABCB1 genotypes are strong predictors of methadone metabolic capacity and plasma exposure. Further investigation is needed to determine their predictive value for methadone treatment outcomes and to develop genotype-based dosing algorithms for safe and effective therapy.

Keyphrases

chronic pain
end stage renal disease
pain management
chronic kidney disease
newly diagnosed
machine learning
ejection fraction
prognostic factors
deep learning
stem cells
genome wide
gene expression
copy number
cell therapy
dna methylation